Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$330.96M+217%-$282.85M-57.2%-$179.95M-$447.51M-381%
$10.59M+102%$5.25M-71.5%$18.45M+70.2%$10.84M+8.6%$9.98M-4.6%
$29.4M-2.1%$30.02M+101%$14.93M-59.7%$37.03M-10.6%$41.43M-16.6%
-$202.68M-$14.59M-$583.44M
$2.08M-42.0%$3.59M-84.3%$22.93M-27.9%$31.8M-27.2%$43.65M+14.6%
-$134.39M-240%$96.21M-$291.18M-138%
$250M$0
$250M+613%$35.09M$0
$241K+101%-$39.21M+66.7%-$117.79M-395%-$23.82M-291%$12.47M-74.5%
-$336.83M-$862.14M-195%
-$204.76M-$37.52M-$627.09M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Sarepta Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.